Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Hermans, Michel P ^a   Ahn, Sylvie A ^a   Rousseau, Michel F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; DISEASE SEVERITY; DYSLIPIDEMIA; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PREVALENCE; BELGIUM; BLOOD; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; HOSPITALIZATION; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; TIME;

AGED; BELGIUM; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 78650008748     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-88     Document Type: Article

References (53)

1. American Diabetes Association Standards of medical care in diabetes - 2009. Diabetes Care 2009, 32:S13-61. 10.2337/dc09-S013, 2613589, 19118286, American Diabetes Association.
2. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996, 124:S57-64. 10.1016/0021-9150(96)05858-3, 8831917.
3. Brites FD, Bonavita CD, De Geitere C, Cloës M, Delfly B, Yael MJ, Fruchart J, Wikinski RW, Castro GR. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000, 152:181-92. 10.1016/S0021-9150(99)00452-9, 10996354.
4. da Luz PL, Favarato D, Faria-Neto JR, Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008, 63:427-32. 2664115, 18719750.
5. Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche J-M, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P, . for the Residual Risk Reduction Initiative The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:S1-34. for the Residual Risk Reduction Initiative.
6. Jones PH. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol 2008, 102:41L-47L. 10.1016/j.amjcard.2008.09.074, 19084089.
7. Rana JS, Visser ME, Arsenault BJ, Després JP, Stroes ES, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT. Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Int J Cardiol 2010, 143:399-404. 10.1016/j.ijcard.2009.03.123, 19394708.
8. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-9. 10.1016/S0140-6736(10)60545-4, 20452521.
9. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-9. 10.1016/S0140-6736(10)60545-4, 2867029, 20452521, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
10. Cordero A, Laclaustra M, León M, Casasnovas JA, Grima A, Luengo E, Ordoñez B, Bergua C, Bes M, Pascual I, Alegría E, . MESYAS Registry Investigators Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol 2008, 102:424-8. 10.1016/j.amjcard.2008.03.079, 18678299, MESYAS Registry Investigators.
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F, . American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-52. 10.1161/CIRCULATIONAHA.105.169404, 16157765, American Heart Association; National Heart, Lung, and Blood Institute.
12. Hermans MP, Fruchart JC. Reducing residual vascular risk in patients with atherogenic dyslipidaemia: where do we go from here?. Clinical Lipidology Review 2010,
13. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-74. 10.1056/NEJMoa1001282, 2879499, 20228404, ACCORD Study Group.
14. Dehout F, Haumont S, Gaham N, Amoussou-Guenou KD, Hermans MP. Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: prevalence, gender differences and HOMA-hyperbolic product. Diab Metab Syndr 2008, 2:5-11.
15. Munoko T, Hermans MP. Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort. Diab Met Syndr 2008, 2:115-24.
16. Sadikot S, Hermans MP. Here we go again ... The metabolic syndrome revisited!. Diab Metab Syndr 2010, 4:111-20.
17. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001, 34:583-8.
18. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008, 101:497-501. 10.1016/j.amjcard.2007.09.109, 18312765.
19. Bittner V, Johnson BD, Zineh I, Rogers WJ, Vido D, Marroquin OC, Bairey-Merz CN, Sopko G. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 2009, 157:548-55. 10.1016/j.ahj.2008.11.014, 2677623, 19249427.
20. Cordero A, Andrés E, Ordoñez B, León M, Laclaustra M, Grima A, Luengo E, Moreno J, Bes M, Pascual I, Civeira F, Pocoví M, Alegría E, Casasnovas JA, . MESYAS (MEtabolic Syndrome Active Subjects) Study Investigators Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol 2009, 104:1393-7. 10.1016/j.amjcard.2009.07.008, 19892056, MESYAS (MEtabolic Syndrome Active Subjects) Study Investigators.
21. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002, 33:1776-81. 10.1161/01.STR.0000020091.07144.C7, 12105351.
22. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. UKPDS 66: risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabetes Care 2004, 27:201-7. 10.2337/diacare.27.1.201, 14693990.
23. Hermans MP, Ahn S, Rousseau MF. Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention. Diabetes Metab Syndr 2008, 2:93-8.
24. Hermans MP, Ahn SA, Rousseau MF. Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes. Diabetes Metab 2009, 35:484-9. 10.1016/j.diabet.2009.06.003, 19897395.
25. Hermans MP, Ahn SA, Rousseau MF. Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea syndrome. Diabetes Metab Syndr 2009, 3:50-4.
26. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-97.
27. Valdez R, Seidell JC, Ahn YI, Weiss KM. A new index of abdominal adiposity as an indicator of risk for cardiovascular disease: a cross-population study. Int J Obes 1992, 16:77-82.
28. Kyle UG, Morabia A, Schutz Y, Pichard C. Sedentarism affects body fat mass index and fat-free mass index in adults aged 18 to 98 years. Nutrition 2004, 20:255-60. 10.1016/j.nut.2003.11.019, 14990265.
29. Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. J Health Econ 2008, 27:519-29. 10.1016/j.jhealeco.2007.05.005, 18166236.
30. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998, 15:290-6. 10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M, 9585393.
31. Levy JC, Matthews DR, Hermans MP. Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-92. 10.2337/diacare.21.12.2191, 9839117.
32. Hermans MP, Levy J, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 1999, 48:1779-86. 10.2337/diabetes.48.9.1779, 10480608.
33. Hermans MP, Levy J, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999, 42:678-87. 10.1007/s001250051215, 10382587.
34. Hermans MP. Diabetic macro- and microvascular disease in type 2 diabetes. Diabetes Vasc Dis Res 2007, 4:S7-11.
35. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-70.
36. Hermans MP, Ahn SA, Rousseau MF. The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: comparison with reference lipid markers. Diab Metab Syndr 2007, 1:23-8.
37. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512-24. 10.1016/j.jacc.2008.02.034, 18402913.
38. Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 2010, 30:239-45. 10.1161/ATVBAHA.109.197830, 19910636.
39. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010, 213:1-7. 10.1016/j.atherosclerosis.2010.03.038, 20451205.
40. Hermans MP, Ahn SA, Rousseau MF. Raised natriuretic peptides, Big-endothelin-1 and improved beta-cell function in type 2 diabetic males with hyperuricaemia. Diab Vasc Dis Res 2009, 6:190-3. 10.1177/1479164109336689, 20368210.
41. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008, 82:S30-7. 10.1016/j.diabres.2008.09.032, 18937992.
42. Hermans MP, Ahn SA, Gruson D, Rousseau MF. The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. Diab Metab Syndr 2007, 1:229-37.
43. Hermans MP, Ahn SA, Amoussou-Guenou KD, Rousseau MF. Impact of metabolic syndrome on microvascular complications in type 2 diabetes. Diab Metab Syndr 2010, 4:150-4.
44. Hermans MP. Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis from FIELD. Curr Cardiol Rev 2010, 6:112-8.
45. Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M. Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism 2010, 59:299-304. 10.1016/j.metabol.2009.07.027, 19796777.
46. Ducobu J, Scheen A, Van Gaal L, Velkeniers B, Hermans M. Belgian Expert opinion: how to reduce the residual risk in atherogenic dyslipidemic patients: place of fibrates. Acta Cardiol 2008, 63:235-48. 10.2143/AC.63.2.2029534, 18468206.
47. Fruchart J-C, Sacks FM, Hermans MP. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i). Curr Med Res Opin 2010, 26:1793-7. 10.1185/03007995.2010.489341, 20482323.
48. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-84. 10.1016/S0140-6736(10)60656-3, 20462635.
49. The ACCORD Study Group and ACCORD Eye Study Group ACCORD Eye. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-44. 10.1056/NEJMoa1001288, 20587587, The ACCORD Study Group and ACCORD Eye Study Group.
50. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-12. 10.1001/jama.281.21.2005, 10359389.
51. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008, 57:2794-800. 10.2337/db08-0450, 2551691, 18599520.
52. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-22. 10.1161/CIRCULATIONAHA.108.836346, 20026785.
53. Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity?. Cardiovasc Diabetol 2008, 7:4. 10.1186/1475-2840-7-4, 2292689, 18307789.